• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.62%

    Trevena, Inc. (TRVN)

    7.79 Down 0.17(2.14%) Apr 29, 4:00PM EDT
    |After Hours : 7.79 0.00 (0.00%) Apr 29, 4:41PM EDT
    ProfileGet Profile for:
    Trevena, Inc.
    1018 West 8th Avenue
    Suite A
    King of Prussia, PA 19406
    United States - Map
    Phone: 610-354-8840
    Website: http://www.trevenainc.com

    Index Membership:N/A
    Full Time Employees:42

    Business Summary 

    Trevena, Inc., a clinical stage biopharmaceutical company, discovers, develops, and intends to commercialize therapeutics for G protein coupled receptors. The company’s central nervous system product pipeline includes Oliceridine, a small molecule G protein biased ligand, which is in Phase III clinical trials for patients experiencing moderate to severe acute pain where IV administration is preferred; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain. Its central nervous system product pipeline also comprises TRV250, a small molecule G protein biased ligand of the delta-opioid receptor, which is in preclinical development stage for the treatment refractory migraine. In addition, the company develops cardiovascular programs, such a TRV027, a peptide beta-arrestin biased ligand that targets the angiotensin II type 1 receptor and is in Phase IIb clinical trials for the treatment of acute heart failure in combination with standard diuretic therapy. Trevena, Inc. was founded in 2007 and is based in King of Prussia, Pennsylvania.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Trevena, Inc.

    Corporate Governance 
    Trevena, Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 9. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 10.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. Maxine Gowen Ph.D., 58
    Chief Exec. Officer, Pres and Exec. Director
    Dr. Michael W. Lark Ph.D., 59
    Chief Scientific Officer and Sr. VP of Research
    Dr. David Soergel M.D., 48
    Chief Medical Officer and Sr. VP of Clinical Devel.
    Dr. Howard A. Rockman M.D.,
    Scientific Founder, Consultant and Member of Scientific Advisory Board
    Dr. Jonathan Violin Ph.D., 41
    Scientific Co-Founder and Sr. Director of Investor Relations
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders